Treatment outcome in a population-based 'real-world' cohort of chronic myeloid leukemia patients.

Treatment outcome in a population-based 'real-world' cohort of chronic myeloid leukemia patients. Haematologica. 2017 Aug 31;: Authors: Geelen IGP, Thielen N, Janssen JJWM, Hoogendoorn M, Roosma TJA, Willemsen SP, Visser O, Cornelissen JJ, Westerweel PE Abstract Real-world evaluations of the efficacy and safety of tyrosine kinase inhibitors in patients with chronic myeloid leukemia are scarce. A nationwide population-based chronic myeloid leukemia registry was analyzed to evaluate (deep) response rates to first and subsequent treatment lines and eligibility for a treatment cessation attempt in adults diagnosed between January 2008 and April 2013 in the Netherlands. The registries covered 457 patients; 434 in chronic (95%) and 15 patients (3%) in advanced disease phase. 75% of the patients in chronic phase were treated with imatinib and 25% with a second generation tyrosine kinase inhibitor. At 3 years 44% of patients had discontinued their first line treatment, mainly due to intolerance (21%) or treatment failure (19%). At 18 months 73% of patients had achieved a complete cytogenetic response and 63% a major molecular response. Deep molecular responses (MR4.0 and MR4.5) were achieved in 69% and 56% of patients at 48 months. All response milestones were achieved faster in patients treated upfront with a second generation tyrosine kinase inhibitor, but ultimately also patients initially treated with imatinib reached similar levels of r...
Source: Haematologica - Category: Hematology Authors: Tags: Haematologica Source Type: research